Compare BlackBerry Limited (BB) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? BlackBerry Limited trades at $10.56 (market cap $6.39B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.45 (market cap $8.04B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and BlackBerry Limited is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BB | BIO | |
|---|---|---|
Market Cap | $6.39B | $8.04B |
Sector | Technology | Health |
52-Week High | $12.81 | $339.75 |
52-Week Low | $3.15 | $241.71 |
Enterprise Value | $6.26B | $7.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $10.71, down 2.37% today, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q1 2026 earnings beat expectations with EPS of $0.06 versus $0.05 expected, driven by QNX software growth. Revenue for 2025 was $534.90M with a net loss of $79M, but 2026 projects a return to profitability. Positive news highlights QNX expansion into robotics and industrial automation.
Outlook is cautiously optimistic as the company's turnaround gains traction, but high valuation ratios (P/E 107.1) and mixed analyst sentiment (14% buy, 86% hold) suggest execution risks remain. Key opportunities include QNX's market penetration, while risks involve competitive pressures and achieving sustained profitability.
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
